Management of cancer pain

Lancet

Volumn 353, Issue 9165, 1999, Pages 1695-1700

  Portenoy, Russell K ^a   Lesage, Pauline ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; FENTANYL; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL;

CANCER PAIN; CANCER PALLIATIVE THERAPY; CHRONIC PAIN; CLINICAL PRACTICE; CONSTIPATION; HUMAN; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION; VOMITING;

EID: 0033562594     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)01310-0     Document Type: Review

References (29)

1. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990; 43: 273-86.
2. Portenoy RK. Pain syndromes in patients with cancer and HIV/AIDS. In: Portenoy RK, ed. Contemporary diagnosis and management of pain in oncologic and AIDS patients. Newtown, PA: Handbooks in Healthcare, 1998: 44-70.
3. WHO. Cancer pain relief and palliative care. Geneva: WHO, 1996.
4. Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999; 79: 303-12.
5. Cherny NI, Portenoy RK. Cancer pain: principles of assessment and syndromes. In: Wall PD, Melzack R, eds. Textbook of pain, 4th edn. Edinburgh: Churchill Livingstone (in press).
6. Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 1994; 3: 183-89.
7. Ventafridda V, DeConno F, Ripamonti C, et al. Quality-of-life assessment during a palliative care programme. Ann Oncol 1990; 1: 415-20.
8. Curtis EB, Krech R, Walsh TD. Common symptoms in patients with advanced cancer. J Palliat Care 1991; 7: 25-29.
9. Portenoy RK. Cancer pain: pathophysiology and syndromes. Lancet 1992; 339: 1026-31.
10. Saunders C. The philosophy of terminal care. In: Saunders C, ed. The management of terminal malignant disease. London: Edward Arnold, 1984: 232-41.
11. Cassell EJ. The nature of suffering and the goals of medicine. N Engl J Med 1982; 306: 639-45.
12. Cherny NI, Coyle N, Foley KM. Suffering in the advanced cancer patient: a definition and taxonomy. J Palliat Care 1994; 10: 57-70.
13. Cella DF. Quality of life: concepts and definition. J Pain Symptom Manage 1994; 9: 186-93.
14. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
15. Jacox A, Carr DB, Payne R, et al. Management of cancer pain. AHCPR publication no. 94-O592: Clinical practice guideline no 9. Rockville, MD: US Department of Health and Human Services, Public Health Service, March, 1994.
16. American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain. Skokie, IL: American Pain Society, 1992.
17. Ingham J, Portenoy RK. Drug therapy for pain: NSAIDS and opioids. Curr Opin Anaesthesiol 1993; 6: 838-44.
18. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 1997; 13: 254-61.
19. Bruera E. Subcutaneous administration of opioids in the management of cancer pain. In: Foley KM, Bonica JJ, Ventafridda V, eds. Advances in pain research and therapy, vol 16. New York: Raven Press, 1990: 203-18.
20. Waldman SD, Leak DW, Kennedy LD, et al. Intraspinal opioid therapy. In: Patt RB, ed. Cancer pain. Philadelphia: JB Lippincott, 1993: 285-38.
21. Derby S, Chin J, Portenoy RK. Systemic opioid therapy for chronic cancer pain: practical guidelines for converting drugs and routes of administration. CNS Drugs 1998; 9: 99-109.
22. Bruera EB, Pereira J, Watanabe S, et al. Systemic opioid therapy for chronic cancer pain: practical guidelines for converting drugs and routes. Cancer 1996; 78: 852-57.
23. Portenoy RK. Management of common opioid side effects during long-term therapy of cancer pain. Ann Acad Med Singapore 1994; 23: 160-70.
24. Derby S, Portenoy RK. Assessment and management of opioid-induced constipation. In: Portenoy RK, Bruera EB, eds. Topics in palliative care, vol 1. New York: Oxford University Press, 1997: 95-112.
25. Doyle E, Hanks GWC, MacDonald N, eds. Oxford textbook of palliative medicine. New York: Oxford University Press, 1998.
26. Vane JRE, Bakhle YS, Botting RM. Cyclooxygenase 1 and 2. Ann Rev Pharmacol Toxicol 1998; 38: 97-120.
27. Portenoy RK. Adjuvant analgesics in pain management. In: Doyle D, Hanks GW, MacDonald N, eds. Oxford textbook of palliative medicine. New York: Oxford University Press, 1998: 361-90.
28. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 1998; 16: 1218-25.
29. Ripamonti C. Management of bowel obstruction in advanced cancer patients. J Pain Symptom Manage 1994; 9: 193-200.